Open Access<p>Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response</p>
Author(s) -
Peidi Yin,
Huifeng Li,
Chao Ke,
Guangxu Cao,
Xiaoqian Xin,
Junjiao Hu,
XiangRan Cai,
Lingfeng Li,
Xiaowen Liu,
Bin Du
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s240551
Subject(s) - temozolomide , glioma , immune system , in vivo , cancer research , nasal administration , pharmacology , drug delivery , chemistry , medicine , biology , microbiology and biotechnology , immunology , organic chemistry
Some chemotherapeutics have been shown to induce both the release of damage-associated molecular patterns (DAMPs) and the production of type I interferon (IFN-I), leading to immunogenic cell death (ICD). However, the standard chemotherapy drug for glioma, temozolomide (TMZ), cannot induce ICD as it cannot activate IFN-I signaling. Moreover, inefficient delivery of immunostimulants across the blood-brain barrier (BBB) is the main obstacle to overcome in order to induce local immune responses in the brain.